News search

The results, published in the European Heart Journal and presented at the European Society of Cardiology Congress, opens the way to new therapies for patients with genetic heart diseases

ESC calls for a cultural shift to deal with the adverse combination of mental health conditions and cardiovascular disease

Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), together with cardiologists from Hospital Universitario Puerta de Hierro and the Spanish cardiovascular disease research network (CIBERCV), report that the new discovery makes it possible to identify high-risk patients early and refer them sooner to specialized heart failure units

Dr. Claudia Monaco, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK

A new study led by the CNIC has identified imidazole propionate (ImP), a metabolite produced by gut bacteria, as a driver of atherosclerosis— as a driver of atherosclerosis, the disease behind most heart attacks and strokes

CNIC researchers have uncovered the evolutionary logic of the OxPhos system—the cell’s “engine”—and developed a tool to detect mutations that cause mitochondrial disease

This new tool will advance the development of treatments for congenital muscle diseases and cardiomyopathies. 

A team from the CNIC has discovered the key role of conventional type 1 dendritic cells (cDC1) in atherosclerosis and has developed an experimental therapy with immunosuppressive nanoparticles that slows the progression of the disease in animal models.